 surrog marker surviv patient aid aid complex zidovudin object earli effect zidovudin treatment lymphocyt count concentr beta microglobulin neopterin hiv antigen antibodi surviv patient aid aid complex design retrospect studi chang laboratori marker surviv set multicentr trial univers hospit clinic subject patient aid aid complex intervent patient mg hour fifti patient median month zidovudin patient median month main outcom measur chang lymphocyt count serum concentr antigen antibodi beta microglobulin surviv patient result pretreat characterist poor surviv multivari proport hazard model diagnosi aid aid complex age year logarithm serum neopterin concentr characterist logarithm lymphocyt count week treatment increas serum beta microglobulin concentr week surviv patient pretreat prognosi month surviv product-limit method good respons surrog marker earli treatment poor respons marker pretreat prognosi month surviv good respons surrog marker poor respons conclus data count week chang serum beta microglobulin concentr surrog end point clinic outcom trial antiretrovir drug patient hiv diseas